Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Diseases of the Thyroid

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 29 articles:
HTML format
Text format



Single Articles


    February 2017
  1. VAN NOSTRAND D
    Prescribed activities of I-131 therapies in differentiated thyroid cancer: Invited Commentary.
    J Nucl Med. 2017 Feb 16. pii: jnumed.116.188862. doi: 10.2967/jnumed.116.188862.
    PubMed     Text format    


  2. FLUX GD, Verburg FA, Chiesa C, Bardies M, et al
    Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.
    J Nucl Med. 2017 Feb 9. pii: jnumed.116.186643. doi: 10.2967/jnumed.116.186643.
    PubMed     Text format    


    January 2017
  3. PLYKU D, Hobbs RF, Huang K, Atkins F, et al
    Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer.
    J Nucl Med. 2017 Jan 19. pii: jnumed.116.179366. doi: 10.2967/jnumed.116.179366.
    PubMed     Text format     Abstract available


    October 2016
  4. LANGEN B, Rudqvist N, Helou K, Forssell-Aronsson EB, et al
    Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Non-Thyroid Tissues.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.176958.
    PubMed     Text format     Abstract available


  5. DEANDREIS D, Rubino C, Tala H, Leboulleux S, et al
    Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.179606.
    PubMed     Text format     Abstract available


  6. SELIVANOVA S, Lavallee E, Senta H, Caouette L, et al
    Clinical Trial Using Sodium Pertechnetate 99mTc Produced with Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.178509.
    PubMed     Text format     Abstract available


    August 2016
  7. YANG X, Li J, Li X, Liang Z, et al
    TERT promoter mutation predicts radioiodine refractory in distant metastatic differentiated thyroid cancer.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.180240.
    PubMed     Text format     Abstract available


    June 2016
  8. KLEIN HESSELINK EN, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, et al
    Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: a prospective study.
    J Nucl Med. 2016 Jun 23. pii: jnumed.115.169888.
    PubMed     Text format     Abstract available


    May 2016
  9. BODET-MILIN C, Faivre-Chauvet A, Carlier T, Rauscher A, et al
    Immuno-PET using anti-CEA bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a First-in Human trial.
    J Nucl Med. 2016 May 26. pii: jnumed.116.172221.
    PubMed     Text format     Abstract available


  10. JENTZEN W, Verschure F, van Zon A, van de Kolk R, et al
    Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging.
    J Nucl Med. 2016 May 19. pii: jnumed.115.170571.
    PubMed     Text format     Abstract available


  11. LIN CY, Lin CL, Kao CH
    Reply: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 19. pii: jnumed.116.178152.
    PubMed     Text format    


  12. CHEN KT, Hu YW
    Letter: Risk of Breast Cancer in Patients with Thyroid Cancer Receiving I-131 Treatment: Is There an Immortal Time Bias?
    J Nucl Med. 2016 May 5. pii: jnumed.116.173641.
    PubMed     Text format    


  13. RUHLMANN M, Jentzen W, Ruhlmann V, Pettinato C, et al
    High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Images in Detecting Iodine-positive Thyroid Cancer Metastases.
    J Nucl Med. 2016 May 5. pii: jnumed.115.169649.
    PubMed     Text format     Abstract available


    March 2016
  14. BINSE I, Poeppel TD, Ruhlmann M, Ezziddin S, et al
    68Ga-DOTATOC-PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin.
    J Nucl Med. 2016 Mar 31. pii: jnumed.115.171942.
    PubMed     Text format     Abstract available


  15. PATTISON DA, Solomon B, Hicks RJ
    A New Theranostic Paradigm for Advanced Thyroid Cancer.
    J Nucl Med. 2016 Mar 31. pii: jnumed.116.173534.
    PubMed     Text format    


  16. GABLER AS, Kuhnel C, Winkens T, Freesmeyer M, et al
    Assessment of minimum activity of 124Iodine in pre-therapeutic uptake measurement prior to radioiodine therapy of benign thyroid diseases.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.171066.
    PubMed     Text format     Abstract available


    February 2016
  17. WIERTS R, Brans B, Havekes B, Kemerink G, et al
    Dose-response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    J Nucl Med. 2016 Feb 25. pii: jnumed.115.168799.
    PubMed     Text format     Abstract available


  18. LIN CM, Yeh PT, Doyle P, Tsan YT, et al
    Association between 131I treatment for thyroid cancer and risk of receiving cataract surgery-a cohort study from Taiwan.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.167197.
    PubMed     Text format     Abstract available


    December 2015
  19. LIN CY, Lin CL, Huang WS, Kao CH, et al
    Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving I-131 Treatment: A Nationwide Population-based Cohort Study.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.164830.
    PubMed     Text format     Abstract available


    November 2015
  20. KIST JW, de Keizer B, van der Vlies M, Brouwers AH, et al
    124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer; results of a multicenter diagnostic cohort study (THYROPET).
    J Nucl Med. 2015 Nov 25. pii: jnumed.115.168138.
    PubMed     Text format     Abstract available


  21. EBERLEIN U, Scherthan H, Bluemel C, Peper M, et al
    DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients after Radioiodine Therapy.
    J Nucl Med. 2015 Nov 12. pii: jnumed.115.164814.
    PubMed     Text format     Abstract available


    September 2015
  22. SINGH TD, Jeong SY, Lee SW, Ha JH, et al
    Inverse agonist of estrogen-related receptor gamma (ERRgamma) enhances sodium iodide symporter function through mitogen-activated protein kinase signaling in anaplastic thyroid cancer cells.
    J Nucl Med. 2015 Sep 3. pii: jnumed.115.160366.
    PubMed     Text format     Abstract available


    August 2015
  23. RYU CH, Ryu J, Ryu YM, Lee YJ, et al
    Radioactive iodine therapy does not affect vocal function within one year after total thyroidectomy.
    J Nucl Med. 2015 Aug 13. pii: jnumed.115.161463.
    PubMed     Text format     Abstract available


    April 2015
  24. JENTZEN W, Bockisch A, Ruhlmann M
    Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using Iodine-124.
    J Nucl Med. 2015 Apr 9. pii: jnumed.114.153031.
    PubMed     Text format     Abstract available



  25. Lenvatinib receives approval in DTC.
    J Nucl Med. 2015;56:12N.
    PubMed     Text format    


    March 2015
  26. NAGARAJAH J, Ho AL, Tuttle RM, Weber WA, et al
    Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: An 18F-FDG-PET study.
    J Nucl Med. 2015 Mar 26. pii: jnumed.114.150607.
    PubMed     Text format     Abstract available


  27. KNOOP K, Schwenk N, Schmohl K, Muller A, et al
    Mesenchymal stem cell (MSC)-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.
    J Nucl Med. 2015 Mar 5. pii: jnumed.114.146662.
    PubMed     Text format     Abstract available


    January 2015
  28. MAIER TM, Schober O, Gerss J, Gorlich D, et al
    Differentiated thyroid cancer patients > 60 years of age paradoxically show an increased life expectancy.
    J Nucl Med. 2015 Jan 22. pii: jnumed.114.150284.
    PubMed     Text format     Abstract available



  29. ACR White Paper Targets Thyroid Incidentaloma Reporting.
    J Nucl Med. 2015;56:12N.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: